Trastuzumab envedotin
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) . Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer[1].
Product Specifications
Product Name Alternative
DP303c
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR
Related Pathways
Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
[Trastuzumabenvedotin]
References & Citations
[1]Zhang J, et al. First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors. NPJ Precis Oncol. 2024 Sep 12;8 (1) :200.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
Phase 3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
